|
The Savvy Consumer
DTC
Ads: A Link to Patient Safety?
In the United States more
money is spent each year to treat the complications of home
medication errors than to pay for prescribed medications.
Why? Patients don't receive enough information or the
right kind of information to manage their medications
safely and effectively.
A recent conference sponsored
by FDA and the National Patient Safety Foundation, "Safe Medical
Treatments: Everyone Has A Role," brought consumers and health
care providers together to discuss ways to improve patient
safety. The message was loud and clear. No medication is safe
and unless the patient uses it correctly. It's not a matter
of blame. Conferees agreed that consumers need adequate information
so they can manage their medications safely.
Research shows that home medication
errors can be cut in half if patients are given high quality
education particularly about the side effects that
may lead to inappropriate patient decisions throughout
their therapy. The question is: "Can DTC ads make an important
contribution to patient safety and help reduce home medication
errors?"
Side-Effect
Dilemma
How much do consumers need to know about side effects? An
FDA study found that almost half of the public believe DTC
ads offer insufficient side-effect information. Consumers
need more than just a simple list of potential side effects.
They need to know what to do if they develop any of the initial
symptoms.
Advertising Age recently
reviewed how DTC advertisers are handling the thorny side-effect
information issue. Quotes from ad agencies and pharmaceutical
companies seem to reflect a growing appreciation of consumer
demands for accurate and practical information about pharmaceutical
products:
"Consumers want to be fully informed,
and that includes both benefits and risks."
"It's to the consumer's benefit
that we share with them what are the most common side effects."
Ad Age illustrated the
article with an ad for Bristol-Myers Squibb's anxiety drug
BuSpar to show how DTC ads give side effects "equal time."
The copy on the ad's front does, in fact, advise readers of
possible drug interactions and that "some people may experience
side effects such as excitement, dizziness, nausea, headache,
lightheadedness, and nervousness."
Unfortunately, those are the
only useful comments the ad gives, because the next line tells
them to turn the page for "additional important information."
There, readers find a Package Insert written for health professionals
and presented in a block of fine print shoehorned into two-thirds
of the page. Thus, although the ad satisfies FDA's requirements
to disclose possible risks, it fails to answer questions consumers
are certain to have.
- How
likely is it the product will make me dizzy or lightheaded?
- Will
this keep me from driving my car or going to work?
- How
can I manage these side effects?
|
Consumer
Feedback
Consumers have
a unique perspective on medication risk management that is
valuable to postmarketing surveillance programs.
A 1999 article, "Understanding
Adverse Drug Reaction Symptoms," published by the Journal
of the Drug Information Association, verified that
"patients want to share information about the drug reactions
they experience." The article revealed that
- more
than 40 percent of ADR reports submitted to FDA are from
consumers, and the number is growing.
- nearly
one-third of reports originating from physicians may be
prompted by patient reports of symptoms and their attribution
to a medication.
The article concluded, "The information
patients have to share about adverse drug reactions does contribute
to our knowledge of drug safety."
If encouraged to report those
experiences to their health professionals and FDA, consumers
will become allies in their own care, enabling pharmaceutical
companies to develop more accurate and practical risk management
information for patients.
DTC ads are a key avenue through
which to deliver that information. Consumers who read the
ads will learn to identify the early symptoms of adverse drug
reactions and can perhaps minimize those effects. And as companies,
in turn, gather more adverse drug reaction information from
consumers, DTC ads will become an increasingly useful tool
to improve patient safety.
Dr.
Dorothy L. Smith is a consumer education expert and president
of Consumer Health Information Corporation. The full-service
company specializes in patient labeling, program development,
and strategic planning for DTC campaigns.
Do
you have a DTC question? E-mail it to dlsmith@consumer-health.com
or call (703)734-0650.
Published
in Pharmaceutical Executive, June 2000. Copyrighted
material; All rights reserved.

|